Aroa Biosurgery (ASX:ARX) said a real-world study showed the efficacy of its Myriad product designed for limb reconstruction procedures, according to a Monday filing with the Australian bourse.

The study, conducted in patients with high risks of complications and amputations, showed that the Myriad Matrix and Myriad Morcells regenerative products were able to achieve full coverage with no infections and complications, the filing said.

The study covered 120 patients with 130 lower limb defects, the filing said. Across all participants, 95% had at least one risk factor for amputation, and 55% had three or more risk factors.

Results were published in the peer-reviewed journal Plastic and Reconstructive Surgery - Global Open.

The company's shares gained close to 2% in recent Monday trade.